You are here:   Content Hub > Pharmavibe > Weekly Pharma News Review (0523-0529)
Discover your favourite episodes effortlessly
PharmaVibe, capture the dynamics of the pharmaceutical industry
Listen and sense the heartbeat of the industry through news stories, key conferences, and in-depth interviews encompassing an array of specialties, sectors, and areas
Subscribe Now
Access more contents on Content Hub >>
Webniars
Industry Reports
Pharma Sources Insight
EPISODE 17 | 12 MIN | 01 June 2022

Weekly Pharma News Review (0523-0529)

EPISODE 17 | 12 MIN | 01 June 2022
#Drug Review #R&D #Business
Weekly Pharma News Review (0523-0529)
Play
Summary
CPhI & P-MEC China officially announced the opening ceremony time of the online exhibition - the main event will be grandly unveiled on June 21. From June 22 to 30, the organizer will launch a series of multilingual themed forums to conduct in-depth discussions on R&D, cold chain transportation, environmental management, injection packaging, and intelligent and continuous manufacturing. While a steady flow of good news kept pouring into the Chinese pharmaceutical market last week. FDA approved Hengrui’s ANDA for Iodixanol Injection while its SHR3680 tablets in treating prostate cancer had conducted Phase III clinical trial successfully. As the icing on the cake, TopAlliance’s COVID-19 oral drug Renmindevir hit the prespecified endpoint.
Timeline
1
PART1 | 00:12
VEC: CPhI & P-MEC China officially announced the opening ceremony time - 21 June 2022
2
PART2 | 01:17
The marketing application for Nanjing Shunxin's TQ-B3139 capsule was accepted
3
PART3 | 01:45
The new indication marketing application for Novartis's Eltrombopag Olamine Tablets was accepted
4
PART4 | 02:06
The marketing application of Hengrui Pharmaceuticals’ Ertugliflozin and Metformin sustained-release tablet, was accepted
5
PART5 | 02:36
Class I biological new drug LY3209590 Injection delivered by Eli Lilly got an implied license for the clinical trial
6
PART6 | 03:03
Genor Biopharma's CD20/CD3 bispecific antibody GB261 got the implied license of Phase I/II clinical trial
7
PART7 | 03:26
The clinical trial application of first-in-class RP903 filed by TopAlliance and Risen had got the implied license
8
PART8 | 03:54
InnoCare announced approval to conduct a Phase II clinical trial of tafasitamab in combination with lenalidomide in China
9
PART9 | 04:30
Qilu Pharmaceutical submitted a clinical trial application for Semaglutide Injection
10
PART10 | 05:01
Daiichi Sankyo's ADC drug DS-7300 targeting CD276 was declared for clinical trials in China
11
PART11 | 05:34
Selumetinib capsule declared by AstraZeneca was included in the Priority Review
12
PART12 | 06:02
European Commission grants conditional approval of Cilta-cel CARVYKTI a conditional marketing authorization
13
PART13 | 06:25
FDA approves dermavant's VTAMA tapinarof cream 1 for the treatment of plaque psoriasis in adults
14
PART14 | 06:46
Hengrui announced that its ANDA application for Iodixanol Injection had been approved by FDA
15
PART15 | 07:13
FDA had accepted Biohaven's NDA application for Zavegepant nasal spray for the acute treatment of migraine in adults
16
PART16 | 07:40
Laekna Therapeutics announced the dosing of the first patients in the US and China in Phase 1b/III clinical trial of afuresertib in breast cancer
17
PART17 | 08:11
Phase III clinical trial of VISEN Pharmaceuticals' lonapegsomatropin met the primary endpoint
18
PART18 | 08:39
Roche's new generation of C5 complement inhibitor crovalimab achieved positive results in Phase III clinical study
19
PART19 | 09:04
TopAlliance Biosciences announced that the Phase III registrational clinical trial of the Renmindevir reached the primary endpoint
20
PART20 | 09:23
Concert Pharmaceuticals reports positive topline results for the first CTP-543 Phase 3 clinical trial in Alopecia Areata
21
PART21 | 09:49
Hengrui Pharmaceuticals announced that a multi-center, randomized, controlled Phase III clinical research met the primary endpoint
22
PART22 | 10:23
WuXi Biologics and Vir Biotechnology terminated antibody collaboration
23
PART23 | 10:46
Henlius licenses rituximab and trastuzumab products to Abbott in Brazil
You can listen and/or download the episode on Podbean, or directly through iTunes, GooglePlay, Amazon Music and Samsung Podcasts. You can also subscribe our podcast by RSS feed, please copy the full URL below.
RSS Feed:
https://feed.podbean.com/PharmaSources/feed.xml
Copy Feed
Full Transcript

CPhI & P-MEC China officially announced the opening ceremony time of the online exhibition - the main event will be grandly unveiled on June 21. While a steady flow of good news kept pouring into the Chinese pharmaceutical market last week. FDA approved Hengrui’s ANDA for Iodixanol Injection while its SHR3680 tablets in treating prostate cancer had conducted Phase III clinical trial successfully. As the icing on the cake, TopAlliance’s COVID-19 oral drug Renmindevir hit the prespecified endpoint. The pharma news review in this episode contains 22 pieces of news covering drug review, R&D and business.

 


 

Drug Review

 

NMPA Marketing

[Application]

1. On May 23, CDE’s official website announced that the marketing application for TQ-B3139 capsule had been submitted by Nanjing Shunxin Pharmaceuticals of Chiatai Tianqing and was accepted. The Phase III clinical trial of TQ-B3139, a new generation of ALK inhibitor, was started in 2019 to evaluate its safety and efficacy in newly treated patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

 

2. On May 24, the CDE official website revealed that the new indication marketing application for Novartis's Eltrombopag Olamine Tablets (Brand name: REVDLADE) was accepted. Eltrombopag Olamine Tablet, developed by Novartis, is a non-peptide thrombopoietin receptor (TPO-R) agonist. The drug was approved for marketing by FDA in November 2008.

 

3. On May 26, CDE announced that the marketing application of Hengrui Pharmaceuticals’ investigational new drug, Ertugliflozin and Metformin sustained-release tablet, had been submitted and accepted. It is a compound sustained release formulation for treating type 2 diabetes mellitus (T2DM), composed of the SGLT2 inhibitor Ertugliflozin and Metformin.

 

 

 

NMPA Clinical Trials

[Approval]

4. On May 24, the CDE official website announced that Class I biological new drug LY3209590 Injection delivered by Eli Lilly got an implied license for the clinical trial. It is proposed to be used for adult patients with type 2 diabetes mellitus who need insulin therapy. LY3209590 is a novel and once-weekly long-acting basal insulin, which has entered Phase III clinical trials globally.

 

5. On May 24, Genor Biopharma Co., Ltd. announced that its CD20/CD3 bispecific antibody GB261 got the implied license of Phase I/II clinical trial. It is proposed to be used for the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

 

6. On May 25, CDE announced that the clinical trial application of first-in-class RP903 filed by TopAlliance and Risen had got the implied license. It is proposed to be used for the PIK3CA-mutated, advanced, and malignant solid tumors. RP903 tablet is an investigational oral small-molecule alpha-specific PI3K inhibitor developed by Risen. TopAlliance has obtained 50% of the global rights and interests of the program through cooperation.

 

7. On May 26, InnoCare Pharma announced that it had received approval to conduct a single-arm, open-label, multicenter Phase II clinical trial evaluating the safety and efficacy of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT). Tafasitamab is a humanized monoclonal antibody targeting CD19 and was introduced by InnoCare Pharma in 2021.

 

[Application]

8. On May 24, Qilu Pharmaceutical submitted a clinical trial application for Semaglutide Injection for the first time in Class 2.2 of chemical drugs and the company becomes the fifth enterprise to compete for Semaglutide in China. CDE has accepted the application the next day. Semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk, was approved for treating type 2 diabetes mellitus in the United States in December 2017, and was then subsequently approved for indications such as obesity.

 

9. On May 26, Daiichi Sankyo's ADC drug DS-7300 targeting CD276 was declared for clinical trials in China, and it is the second ADC drug directed against the same target in China. Designed with Daiichi Sankyo's proprietary DXd ADC technology, DS-7300 is composed of a humanized anti-B7-H3 IgG1 monoclonal antibody conjugated to topoisomerase I inhibitor payload exatecan derivative via a tetrapeptide-based cleavable linker.

 

[Priority Review]

10. On May 25, CDE announced that the Selumetinib capsule declared by AstraZeneca was included in the Priority Review and it is proposed to be used for the treatment of pediatric patients aged 3 years and older with the symptomatic, inoperable Neurofibromatosis Type I (NF1) of Plexiform Neurofibromatosis (PN). Selumetinib is a MEK inhibitor co-developed by AstraZeneca and MSD.

 

EMA

11. On May 26, LEGN.US announced that the European Commission (EC) had granted Cilta-cel (brand name: CARVYKTI) a conditional marketing authorization for the treatment of adult patients with relapsed/refractory multiple myeloma (R/RMM), which received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody, and demonstrated disease progression on the last therapy.

 

FDA

[Approval]

12. On May 24, Dermavant Sciences announced that FDA approved VTAMA (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class, and the first topical novel chemical entity launched for psoriasis in the United States in 25 years.

 

13. On May 25, Hengrui announced that its ANDA application for Iodixanol Injection had been approved by FDA. At present, no similar generic drug products have been approved for marketing except in China. Besides Hengrui, multiple Chinese companies have obtained the approval for Iodixanol Injection production such as Yangtze River Pharmaceutical Group, Nanjing Chiatai Tianqing, and Beijing Beilu Pharmaceutical.

 

[Application]

14. On May 23, Biohaven announced that FDA had accepted its NDA application for Zavegepant nasal spray for the acute treatment of migraine in adults. The PDUFA goal date for completion of NDA is set for Q1 2023. The potential approval of Zavegepant will lead to the first and only intranasally dosed small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.

 


 

R&D

Clinical trials launching

15. On May 26, Laekna Therapeutics announced dosing of first patients in the US and China, respectively, in a global multi-center, Phase 1b/III clinical trial of afuresertib in breast cancer. Subject enrollment was initiated at the same time at the Piedmont Cancer Center in Atlanta, US and Tianjin Medical University Cancer Institute & Hospital in China. Afuresertib is a new generation small molecule potent inhibitor of AKT kinase.

 

Clinical data release

16. On May 23, VISEN Pharmaceuticals announced that the Phase III clinical trial of lonapegsomatropin it introduced had met the primary endpoint - Once-Weekly dosed lonapegsomatropin demonstrated superior efficacy to daily growth hormone dosing in the treatment of children with growth hormone deficiency (GHD). Lonapegsomatropin, a long-acting drug that releases unmodified growth hormone at a controlled rate, is also the first FDA-approved product to deliver growth hormone through sustained release in a one-week period.

 

17. On May 23, Roche announced that its new generation of C5 complement inhibitor crovalimab has achieved positive results in Phase III clinical study (COMMODORE3) in treating patients with paroxysmal nocturnal hemoglobinuria (PNH). COMMODORE3 is a multicenter, single-arm Phase III clinical study conducted only in China. The innovative drug crovalimab is expected to be launched in China as the world’s first release.

 

18. On May 23, TopAlliance Biosciences announced that the Phase III registrational clinical trial (NCT05341609) of the Renmindevir (VV116/JT001), an oral nucleoside analog candidate for COVID-19 developed in cooperation with Vigonvita, reached the primary endpoint of “time to sustained clinical recovery” in a head-to-head battle with Pfizer's Paxlovid pill (Ritonavir tablet) for early treatment of mild to moderate COVID-19.

 

19. On May 23, Concert Pharmaceuticals announced that the Phase III clinical trial (THRIVE-AA1) of its oral JAK inhibitor CTP-543 in adult patients with moderate to severe alopecia areata met primary endpoint and key secondary endpoints. Compared to the placebo group, 41.5% of patients in the high-dose group (12mg twice-daily dose group) achieved 80% or more scalp hair coverage after 24 weeks of treatment.

 

20. On May 25, Hengrui Pharmaceuticals announced that a multi-center, randomized, controlled Phase III clinical research met the primary endpoint. The research compared the SHR3680 tablets combined with androgen ablation therapy (ADT) to the standard therapy combined with ADT in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with a high tumor burden. SHR3680 tablets can significantly prolong the overall survival of mHSPC patients with a high tumor burden.

 

 

 

Business

 

21. On May 23, WuXi Biologics announced that it had terminated the authorization agreement with GSK's Vir Biotechnology for the COVID-19 neutralizing antibody Sotrovimab. In February 2022, with the emergence of the omicron sub-variant BA.2, the FDA restricted the use of sotrovimab, saying the drug should not be used for mutant strains of the virus that are insensitive to the antibody.

 

22. On May 24, Henlius announced that it had signed a product license agreement with Abbott, agreeing to grant Abbott a semi-exclusive license for the commercialization of Hanlikang and Hanquyou in the Federative Republic of Brazil and in the territory, as well as a non-exclusive license to produce licensed products as an alternate manufacturer or to commission an alternate manufacturer.

Read More
The World’s First  FDA-Approved Therapy to Improve Renal Function of Adult HRS Patients
EPISODE 22 |  16 MIN  |  20 Sep. 2022
#Drug Review #R&D #Business
This week, in China, Humanwell Healthcare's Class 1.2 traditional Chinese medicine was approved for marketing. Pearl Bio's Bozitinib enteric capsule was planned to be included for priority approval. While globally, the terlipressin injection became the world's first FDA-approved therapy to improve renal function in adult patients with hepatorenal syndrome (HRS).
Play
The marketing declaration of Eli Lilly's hypoglycemic drug tirzepatide in China
EPISODE 21 |  16 MIN  |  14 Sep. 2022
#Drug Review #R&D #Business
This week, the most noteworthy event is Eli Lilly's hypoglycemic drug tirzepatide, a GIP/GLP-1 double agonist, was declared for marketing in China. In the meanwhile, there comes some good news for clinical trial applications of various important drugs. On the R&D side, the pivotal Phase III clinical trials of several drugs have shown positive results, which are related to thyroid carcinoma, pulmonary interstitial fibrosis, migraine, plaque psoriasis, and other indications. The news review of this week is from September 5 to 9, covering a total of 25 pieces of information in 3 sections, i.e., drug review, R&D, and business.
Play
The First and Only TIGIT/TGFβ Bispecific Antibody Under Research in the World
EPISODE 20 |  16 MIN  |  07 Sep. 2022
#Drug Review #R&D #Business #Listing
The marketing approval of SinoCellTech's new anti-CD20 monoclonal antibody ripertamab aroused the attention of the industry in China this week. While the clinical trial application of the AK130 injection developed by another Chinese company Akeso was accepted, making it the first and the only TIGIT/TGFβ bispecific antibody under research in the world. Other pharma news collected this week features 26 pieces of information covering topics on drug review, R&D, business, and listing.
Play
EU issues GMP Annex 1 final revision for sterile drug products
EPISODE 19 |  12 MIN  |  30 Aug. 2022
#Drug Review #R&D #Business #Policy
In the last week's Chinese pharma market, the 11th indication of BeiGene’s PD-1 Tislelizumab was declared for marketing for the treatment of esophageal squamous cell carcinoma. While in the global pharma market, Johnson & Johnson’s Teclistamab was approved by the EC, making it the first BCMA/CD3 bispecific antibody approved for marketing worldwide. In addition, the EU officially released the eagerly anticipated final revision of its GMP Annex 1 for sterile drug products. Other pharma news collected in this episode covers 4 sections including drug review, R&D, business, and policy.
Play
Subscribe Now